Phase 3 Clinical Trials With Primary Completion Dates in August 2017
This is a list of Phase 3 trials with primary completion dates in August 2017 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ADMS | Adamas Pharmaceuticals, Inc. | 2017-08-01 | Phase 3 | NCT02202551 | Open-Label Safety Study of ADS-5102 in PD Patients With LID |
| ARDX | Ardelyx, Inc. | 2017-08-01 | Phase 3 | NCT02686138 | A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C |
| BIVV | Bioverativ Inc. | 2017-08-01 | Phase 3 | NCT01454739 | Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A |
| BIVV | Bioverativ Inc. | 2017-08-01 | Phase 3 | NCT01425723 | Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B |
| CEMP | Cempra, Inc. | 2017-08-01 | Phase 3 | NCT02210325 | Efficacy and Safety Study of Oral Solithromycin Compared to Intramuscular Ceftriaxone Plus Oral Azithromycin in the Treatment of Patients With Gonorrhea |
| CTIC | CTI BioPharma Corp. | 2017-08-01 | Phase 3 | NCT01321541 | Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant |
| DBVT | DBV Technologies S.A. | 2017-08-01 | Phase 3 | NCT02636699 | Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy |
| DRRX | DURECT Corporation | 2017-08-01 | Phase 3 | NCT02574520 | Trial of Extended Release Bupivacaine for Pain Relief After Surgery |
| EGLT | Egalet Corporation | 2017-08-01 | Phase 3 | NCT02716857 | Efficacy and Safety of Egalet-002 in Patients With Moderate-to-Severe Chronic Low Back Pain |
| ENDP | Endo International plc | 2017-08-01 | Phase 3 | NCT00356213 | Comparison of Laparoscopic Sleeve Gastrectomy and Roux-Y-gastric Bypass in the Treatment of Morbid Obesity |
| KALA | Kala Pharmaceuticals, Inc. | 2017-08-01 | Phase 3 | NCT02819284 | Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease |
| KALA | Kala Pharmaceuticals, Inc. | 2017-08-01 | Phase 3 | NCT02813265 | Safety and Efficacy of KPI-12 in Subjects With Dry Eye Disease |
| LIVN | LivaNova PLC | 2017-08-01 | Phase 3 | NCT03014180 | Clinical Evaluation of LEft VEntricular Auto Threshold Alogrithm (LEVEA) |
| MTFB | Motif Bio plc | 2017-08-01 | Phase 3 | NCT02607618 | Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-2 |
| NBRV | Nabriva Therapeutics plc | 2017-08-01 | Phase 3 | NCT02813694 | Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia |
| NDRM | NeuroDerm Ltd. | 2017-08-01 | Phase 3 | NCT02782481 | A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations |
| NURO | NeuroMetrix, Inc. | 2017-08-01 | Phase 3 | NCT02809846 | Quell Opioid Reduction and Pain Relief in Patients With Cancer |
| ORPN | Bioblast Pharma Ltd. | 2017-08-01 | Phase 3 | NCT02328482 | Continuation Protocol to Protocol BBCO-001 |
| RARE | Ultragenyx Pharmaceutical Inc. | 2017-08-01 | Phase 3 | NCT02537431 | Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH) |
| VSAR | Versartis, Inc. | 2017-08-01 | Phase 3 | NCT02339090 | Versartis Long-Acting Growth Hormone in Children Compared to Daily rhGH |
| ZGNX | Zogenix, Inc. | 2017-08-01 | Phase 3 | NCT02926898 | A Two-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children â¥2 Years Old and Young Adults With Dravet Syndrome |